Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aquavit Pharmaceuticals and Green Cross have signed a memorandum of understanding (MOU) on IBX-001 product development and commercialization in Asia.
Subscribe to our email newsletter
According to the MOU, Green Cross will receive an exclusive license to commercialize Aquavit’s IBX-001 in Korea and will support the product development, registration and manufacturing.
Aquavit chief executive officer Sobin Chang said the company has collaborated with Green Cross, a reputable company with firm presence in Asia-Pacific.
"We aim to be a global leader with our innovative personalized treatments through strategic partnerships," Chang added.
The MOU further outlines potential partnerships for other product development and commercialization, according to Aquavit.
Green Cross is a publicly traded Korean biopharmaceutical company that specializes in the development and commercialization of vaccines, plasma-derivatives, recombinant proteins, and therapeutic antibodies for use in the fields of oncology and infectious disease.
Aquavit is a multi-specialty healthcare company focused on discovering, developing and commercializing pharmaceuticals, medical device, and health technologies.